Capecitabine/oxaliplatin (XELOX) versus XELOX plus bevacizumab (XELOX + bev) cost-effectiveness for metastatic colorectal cancer (mCRC) in first line treatment: a Brazilian public hospital analysis

• Author(s): Nunes, Altacílio Aparecido
• Date: 2016
• Origin: Oasisbr
• Subject(s): METÁSTASE NEOPLÁSICA
• Document Type: Other
• Language: Portuguese